Key Advisors


    Barbara Weber, MD

    Senior Advisor, Oncology Therapeutics
  • Barbara Weber, M.D. - Senior Advisor, Oncology Therapeutics

    Barbara Weber, M.D., brings over 25 years of experience working in oncology research, where she has been widely published and received numerous academic and research awards for her work. She is currently an Entrepreneur-in-Residence at Third Rock Ventures. Barbara’s academic research focused on inherited susceptibility to breast cancer and cancer genomics as Professor of Medicine and Genetics at the University of Pennsylvania. She joined GlaxoSmithKline in 2005 where she served as Vice President of three groups, including Global Biomarkers, Oncology Discovery and Translational Medicine, and Cancer Metabolism Drug Discovery. She joined Novartis in 2009, where she held the position of Senior Vice President and Global Head of early development for Novartis Oncology. In this role, she was responsible for all early clinical and translational scientific functions, including trial design and execution, implementation of patient selection strategies and continuation of translational support through full development. Barbara is a member of the honorary societies American Association of Physicians and the American Society for Clinical Investigation, of which she served as President in 2005. Barbara has also served on numerous scientific advisory boards, including the NCI Board of Scientific Advisors and on the Board of Directors of both the American Society of Clinical Oncology and the American Association of Cancer Research. Barbara is a graduate of the University of Washington School of Medicine, she completed her residency in Internal Medicine at Yale University School of Medicine and her fellowship in Medical Oncology at the Dana-Farber Cancer Institute.

    Stefan Knapp, PhD

    SAB Member
  • Stefan Knapp, Ph.D. - SAB Member

    Stefan Knapp, Ph.D., is a Professor at the Department of Pharmaceutical Chemistry at the Goethe University in Frankfurt (Germany) and a visiting Professor at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK), where he was previously a Professor and Director for Chemical Biology at the Target Discovery Institute. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules acting as reader domains of the epigenetic code. He studied chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his Ph.D. in protein crystallography at the Karolinska Institute in Stockholm (Sweden) and continued his career at the Karolinska Institute as a postdoctoral scientist. He was also a principal research scientist in structural biology and biophysics at Pharmacia Corporation.

    Jack Taunton, PhD

    SAB Member
  • Jack Taunton, Ph.D. - SAB Member

    Jack Taunton, Ph.D., is a Professor in the Department of Cellular and Molecular Pharmacology at the UC San Francisco. His research focuses on the design and discovery of chemical tools to modulate proteins in cells, with the aim of demystifying complex cellular processes relevant to human disease. Areas of interest include the structure-based design of reversible and irreversible covalent inhibitors, as well as mechanistic studies of biologically active natural products. Jack has been named an Alfred P. Sloan Fellow, a Searle Scholar, and a Howard Hughes Medical Institute investigator. He is a founder and board observer of Principia BioPharma and a co-founder of Global Blood Therapeutics (NASDAQ: GBT).

    William Weis, PhD

    Advisor, Structural Biology
  • William Weis, Ph.D. - Advisor, Structural Biology

    Bill Weis, Ph.D., has been a faculty member at Stanford University since 1993, where he is a Professor in the Departments of Structural Biology, of Molecular & Cellular Physiology, and of Photon Science. He has been Chair of the Department of Photon Science since 2013 and Chair of the Department of Structural Biology since 2014. Bill received his Bachelor’s of Arts in biochemical sciences from Princeton, his Ph.D. in Biochemistry from Harvard in 1987, and then completed post-doctoral research in biophysics at Yale and Columbia. His current research interests focus on the molecular basis of the development and maintenance of eukaryotic cell and tissue structure, with the principal areas of focus being intracellular adhesion, cell polarity, and the Wnt signaling pathway.

    Daniel F. Veber, PhD

    SAB Member
  • Daniel F. Veber, Ph.D. - SAB Member

    Daniel Veber, Ph.D., has held leadership positions in the pharmaceutical industry and is a recognized expert in the field of medicinal chemistry. From 1993-2002 he was a director for Medicinal Chemistry at GlaxoSmithKline and prior to the merger, SmithKline Beecham, having responsibility for projects relating to bone disease, inflammation, cancer and combinatorial chemistry. Previously, he was Senior Director for Medicinal Chemistry at the Merck Research Laboratories where he worked for a total of 29 years. His responsibilities at Merck covered projects relating to cardiovascular, ophthalmic, CNS, gastrointestinal and antiviral therapeutics. His principal research interests during 37 years of medicinal chemistry have involved the design and synthesis of bioactive peptides and peptidomimetics that are hormone agonists or antagonists and protease inhibitors. He is the author of over 215 publications and inventor of 70 issued U.S. patents. He has received several awards including The Ralph F. Hirschmann Award in Peptide Chemistry from the American Chemical Society and the Allen E. Pierce award (now the Merrifield award) from the American Peptide Society. Daniel is currently applying his experience in medicinal chemistry as a Drug Discovery Consultant and member of Scientific Advisory Boards.